Literature DB >> 33487427

A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer.

Kenji Suzuki1, Shun-Ichi Watanabe2, Masashi Wakabayashi3, Hisashi Saji4, Keiju Aokage5, Yasumitsu Moriya6, Ichiro Yoshino7, Masahiro Tsuboi5, Shinichiro Nakamura8, Kenichi Nakamura3, Tetsuya Mitsudomi9, Hisao Asamura10.   

Abstract

BACKGROUND: The optimal mode of surgery for ground-glass opacity dominant peripheral lung cancer defined with thoracic thin-section computed tomography remains unknown.
METHODS: We conducted a single-arm confirmatory trial to evaluate the efficacy and safety of sublobar resection for ground-glass opacity dominant peripheral lung cancer. Lung cancer with maximum tumor diameter 2.0 cm or less and with consolidation tumor ratio 0.25 or less based on thin-section computed tomography were registered. The primary end point was 5-year relapse-free survival. The planned sample size was 330 with the expected 5-year relapse-free survival of 98%, threshold of 95%, 1-sided α of 5%, and power of 90%. The trial is registered with University Hospital Medical Information Network Clinical Trials Registry, number University Hospital Medical Information Network 000002008.
RESULTS: Between May 2009 and April 2011, 333 patients were enrolled from 51 institutions. Median age was 62 years (interquartile range, 56-68), and 109 were smokers. Median maximum tumor diameter was 1.20 cm (1.00-1.54). Median maximum tumor diameter of consolidation was 0 (0.00-0.20). The primary end point, 5-year relapse-free survival, was estimated on 314 patients who underwent sublobar resection. Operative modes were 258 wide wedge resections and 56 segmentectomies. Median pathological surgical margin was 15 mm (0-55). The 5-year relapse-free survival was 99.7% (90% confidence interval, 98.3-99.9), which met the primary end point. There was no local relapse. Grade 3 or higher postoperative complications based on Common Terminology Criteria for Adverse Effect v3.0 were observed in 17 patients (5.4%), without any grade 4 or 5.
CONCLUSIONS: Sublobar resection with enough surgical margin offered sufficient local control and relapse-free survival for lung cancer clinically resectable N0 staged by computed tomography with 3 or fewer peripheral lesions 2.0 cm or less amenable to sublobar resection and with a consolidation tumor ratio of 0.25 or less.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  GGO; lung cancer; prognosis; sublobar resection

Mesh:

Year:  2020        PMID: 33487427     DOI: 10.1016/j.jtcvs.2020.09.146

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  28 in total

1.  Development and validation of qualitative and quantitative models to predict invasiveness of lung adenocarcinomas manifesting as pure ground-glass nodules based on low-dose computed tomography during lung cancer screening.

Authors:  Jieke Liu; Xi Yang; Yong Li; Hao Xu; Changjiu He; Haomiao Qing; Jing Ren; Peng Zhou
Journal:  Quant Imaging Med Surg       Date:  2022-05

Review 2.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

3.  DNA methylation patterns at and beyond the histological margin of early-stage invasive lung adenocarcinoma radiologically manifested as pure ground-glass opacity.

Authors:  Ziqi Jia; Yadong Wang; Jianchao Xue; Xiaoying Yang; Zhongxing Bing; Chao Guo; Chao Gao; Zhenhuan Tian; Zhenzhen Zhang; Hualei Kong; Qiye He; Zhixi Su; Yiying Liu; Yang Song; Dianjing Liang; Naixin Liang; Shanqing Li; Yuan Gao
Journal:  Clin Epigenetics       Date:  2021-08-19       Impact factor: 6.551

4.  The importance of being solid for a ground glass opacity of the lung.

Authors:  Luca Bertolaccini; Lorenzo Spaggiari
Journal:  Ann Transl Med       Date:  2021-07

5.  Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings.

Authors:  Atsushi Kagimoto; Takeshi Mimura; Atsushi Kamigaichi; Yoshinori Yamashita
Journal:  BMC Cancer       Date:  2022-04-28       Impact factor: 4.638

Review 6.  Transition of Treatment for Ground Glass Opacity-Dominant Non-Small Cell Lung Cancer.

Authors:  Yoshinori Handa; Yasuhiro Tsutani; Morihito Okada
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

7.  Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules.

Authors:  Xiang-Peng Chu; Zi-Hao Chen; Shao-Min Lin; Jia-Tao Zhang; Zhao-Wen Qiu; Wen-Fang Tang; Rui Fu; Zhen-Bin Qiu; Xue-Ning Yang; Yi-Long Wu; Qiang Nie; Wen-Zhao Zhong
Journal:  Transl Lung Cancer Res       Date:  2021-04

8.  Comparison of Perioperative Outcomes Between Precise and Routine Segmentectomy for Patients With Early-Stage Lung Cancer Presenting as Ground-Glass Opacities: A Propensity Score-Matched Study.

Authors:  Xianning Wu; Tian Li; Chuankai Zhang; Gao Wu; Ran Xiong; Meiqing Xu; Dan Su; Mingran Xie
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

9.  Comparison of surgical outcomes and prognosis between wedge resection and simple Segmentectomy for GGO diameter between 2 cm and 3 cm in non-small cell lung cancer: a multicenter and propensity score matching analysis.

Authors:  Yaodong Zhou; Tao Yu; Yixin Zhang; Liqiang Qian; Qing Xia
Journal:  BMC Cancer       Date:  2022-01-16       Impact factor: 4.430

Review 10.  Identifying Lung Cancer Patients Suitable for Segmentectomy: A Brief Review.

Authors:  Chunguo Wang; Sikai Wu; Rongwei Zhang; Ke Jin; Yicheng Qian; Ning Mao; Yun Liu; Miao Zhang; Ke Zhang; Renfeng Wang; Gang Huang; Min Zhang; Baofu Chen; Jianfei Shen
Journal:  Front Surg       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.